In conclusion, in patients with advanced HCC, first-line treatment with lenvatinib plus anti-PD-1 antibodies resulted in a better tumor response in MVTT compared to intrahepatic lesions. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.